Seasonal R21 Mass Vaccination for Malaria Elimination (SERVAL)

This is a cluster randomized trial to determine the impact of seasonal R21/MM mass vaccination (all ages) on malaria transmission and morbidity. Fifty-four villages (30 in The Gambia and 24 in Burkina Faso) will be randomized to either mass vaccination with R21 or no mass vaccination.

The primary objective is to compare in intervention and control clusters the prevalence of malaria (all age groups) at peak transmission after seasonal mass vaccination with R21 (3 monthly doses).

Secondary objectives are:

  1. To assess the safety and tolerability of R21 through spontaneously reported adverse events.
  2. To compare in intervention and control clusters the incidence of malaria infection (all age groups) during the malaria transmission season following seasonal mass vaccination with R21 (3 monthly doses).
  3. To compare in intervention and control clusters the incidence of clinical malaria (all age groups) after seasonal mass vaccination with R21 (3 monthly doses).
  4. To compare in intervention and control clusters the prevalence of malaria (all age groups) at peak transmission after one booster dose of R21.
  5. To compare in intervention and control clusters the incidence of malaria infection (all age groups) during the malaria transmission season following one booster dose of R21.
  6. To compare in intervention and control clusters the incidence of clinical malaria (all age groups), after one booster dose of R21.
  7. To determine the coverage of seasonal mass vaccination with R21 (primary series of three vaccinations and booster) in intervention clusters and related socio-cultural factors
  8. To estimate the cost of seasonal mass vaccination with R21 administration.
  9. To estimate the cost-effectiveness of seasonal mass vaccination with R21 compared to standard malaria control measures.

The exploratory objective is to determine whether serological markers can detect changes in malaria transmission following mass vaccination with R21.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This is a cluster-randomized controlled trial. Fifty-four villages (30 in The Gambia and 24 in Burkina Faso) will be randomized to either mass vaccination with R21 or no mass vaccination. Therefore,15 medium-sized (200-600 people) villages in The Gambia and 12 medium-sized (200-600 people) villages in Burkina Faso will receive the intervention. All study villages will receive standard control intervention, e.g., seasonal malaria chemoprevention, insecticide-treated bed nets, implemented by the National Malaria Control Program and according the National Strategic Plan for malaria control. Mass vaccination will be completed before the start of the malaria transmission season, i.e. July.

A cross-sectional survey to estimate malaria prevalence will be implemented at peak transmission, both following the mass vaccination with 3 doses (first year) and the booster dose (second year). A blood sample will be collected during the malaria transmission season from a cohort of randomly selected individuals to determine the incidence of malaria infection. A system of passive case detection to determine the incidence of clinical malaria will be set up throughout the study period, with special attention to the malaria transmission season (July-December).

Study Type

Interventional

Enrollment (Estimated)

16200

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Nanoro, Burkina Faso
        • Recruiting
        • Clinical Research Unit of Nanoro, Burkina Faso
        • Principal Investigator:
          • Halidou Tinto, PhD
        • Contact:
          • Magloire Natama, PhD
        • Sub-Investigator:
          • Magloire Natama, PhD
      • Fajara, Gambia, 273
        • Recruiting
        • MRC Unit The Gambia at LSHTM
        • Contact:
        • Principal Investigator:
          • Umberto D'Alessandro, MD, MSc, PhD
        • Sub-Investigator:
          • Annette Erhart, MD, MSc, PhD
        • Sub-Investigator:
          • Edgard Dabira, MD, MSc, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Age≥ 5 months.
  2. Willingness to comply with trial procedures.
  3. Individual written informed consent obtained at the beginning of the study.

Exclusion Criteria:

  1. Pregnancy
  2. History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, e.g., Kathon, neomycin, betapropiolactone.
  3. Any history of anaphylaxis in relation to vaccination.
  4. Known chronic illness.
  5. Any other significant disease, disorder or situation which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Experimental Group
Three monthly doses of R21/MM will be administered to all eligible residents in the 27 intervention villages (15 in The Gambia and 12 in Burkina Faso), starting from May 2024, with the aim of having completed the vaccination schedule by end of July 2024, before the malaria transmission season starts. A booster vaccine dose will be administered in June 2025 to all eligible individuals who received at least one vaccine dose the previous year. Residents who are eligible but not vaccinated in the previous year, will be offered a complete vaccination schedule, i.e. 3 monthly doses, starting from April. After each vaccination, the first 100 vaccinated individuals will be visited at home daily, for 3 consecutive days, and then at day 7 after the vaccination to collect local and systemic adverse events (AE). Vaccinated individuals (or their parents) will be asked to report to the nurse based in their study village any illness occurring during the 28 days after vaccination.
A mixture of R21/Matrix M at a dose of 5 μg (for children up to 14 years of age) or 10 μg ( for individuals ≥ 15 years old) with 50 μg of Matrix-M will be administered monthly over 3 months (one dose per month over 3 months (May, June, and July 2024) plus a booster dose in June 2025.
No Intervention: Control Group
Only standard malaria control measures ( Malaria Chemoprevention (SMC), Intermittent Preventive Treatment during pregnancy (IPTp), Insecticide-Treated bed Nets (ITN), prompt diagnosis and treatment of patients with uncomplicated malaria and Indoor Residual Spraying (IRS)) will be implemented in control villages.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of malaria infection by PCR in all age groups at peak transmission season (October-November) following the first vaccination with 3 doses.
Time Frame: At 6 months ( October - November 2024) post first round of vaccination
A cross-sectional survey will be conducted at peak transmission in October -November 2024 to determine prevalence of malaria infection.
At 6 months ( October - November 2024) post first round of vaccination

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Occurrence of Adverse Events (AEs) during follow up.
Time Frame: Up to 28 days post vaccination
  1. Occurrence of solicited local and/or systemic reactogenicity
  2. Occurrence of unsolicited adverse events
  3. Occurrence of abnormal hematology and biochemistry parameters ( clinically significant values)
  4. Occurrence of serious adverse events ( throughout the trial)
Up to 28 days post vaccination
Incidence of malaria infection in all age groups during the transmission season following mass vaccination with R21
Time Frame: Up to 6 months post the third vaccination round
Incidence of malaria infection will be determined by molecular analyses (PCR) in a cohort of 20 individuals per village in Burkina Faso and 30 individuals per villages in The Gambia through monthly home visits ( following mass vaccination with R21).
Up to 6 months post the third vaccination round
Incidence of clinical malaria in all age groups following mass vaccination with R21.
Time Frame: Up to 6 months post the third vaccination round
A passive case detection of clinical malaria throughout the study period, with special attention to the malaria transmission season (July-December)
Up to 6 months post the third vaccination round
Prevalence of malaria infection by PCR in all age groups at peak transmission following the booster dose.
Time Frame: At 6 months ( October - November 2025) post booster dose
A cross-sectional survey will be conducted at peak transmission in October -November 2025 to determine prevalence of malaria infection.
At 6 months ( October - November 2025) post booster dose
Incidence of malaria infection in all age groups during the transmission season following the booster dose.
Time Frame: Up to 6 months post booster dose
Incidence of malaria infection will be determined by molecular analyses (PCR) in a cohort of 20 individuals per village in Burkina Faso and 30 individuals per villages in The Gambia through monthly home visits ( following the booster dose).
Up to 6 months post booster dose
Incidence of clinical malaria in all age groups following the booster dose.
Time Frame: Up to 6 months post the third vaccination round
Passive detection of clinical malaria both at the community and at health facility level
Up to 6 months post the third vaccination round
Coverage of completed vaccination schedule (3 doses) during the mass vaccination with 3 doses.
Time Frame: Up to 4 weeks post the third vaccination round
Coverage of completed vaccination schedule (3 doses) during the mass vaccination with 3 doses.
Up to 4 weeks post the third vaccination round
Coverage of at least one vaccine dose administered during the mass vaccination with 3 doses
Time Frame: Up to 4 weeks post the third vaccination round
Coverage of at least one vaccine dose
Up to 4 weeks post the third vaccination round
Coverage of the booster dose
Time Frame: Up to 4 weeks post booster dose
Coverage of the booster dose
Up to 4 weeks post booster dose
Cost of vaccine administration and cost effectiveness, both for the mass vaccination campaign with 3 doses and the booster dose.
Time Frame: Up to 6 months post booster dose
A cross sectional survey will be carried out at the beginning of the project in both study arms to estimate the cost of seeking care among households and the costs supported by the health facility. Cost of mass vaccination will be collected for each round.
Up to 6 months post booster dose

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Umberto D'Alessandro, MD, MSc, PhD, MRCG at LSHTM
  • Principal Investigator: Halidou Tinto, PhD, Clinical Research Unit of Nanoro (CRUN)
  • Study Director: Edgard Dabira, MD, MSc, PhD, MRCG at LSHTM
  • Study Director: Magloire Natama, PhD, Clinical Research Unit of Nanoro, Burkina Faso

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 30, 2024

Primary Completion (Estimated)

December 31, 2024

Study Completion (Estimated)

December 31, 2025

Study Registration Dates

First Submitted

March 27, 2024

First Submitted That Met QC Criteria

August 27, 2024

First Posted (Actual)

August 29, 2024

Study Record Updates

Last Update Posted (Actual)

August 29, 2024

Last Update Submitted That Met QC Criteria

August 27, 2024

Last Verified

August 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Anonymised IPD data will be made available from one month after trial publication and for a further 24 months

IPD Sharing Time Frame

1 month after the publication date and for a further 24 months

IPD Sharing Access Criteria

Application to the principal investigator with a justification of the request

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe